Your SlideShare is downloading. ×
  • Like
Emerging markets in India / Surbhi Sharma, Secretary General Interactive Technology Software and Media Association, Índia
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Emerging markets in India / Surbhi Sharma, Secretary General Interactive Technology Software and Media Association, Índia

  • 1,640 views
Published

Sra. Surbhi Sharma, …

Sra. Surbhi Sharma,
Secretary General Interactive Technology Software and Media Association, Índia.

Published in Business
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
1,640
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
19
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. EMERGING MARKETS IN INDIA EMERGING MARKETS IN  INDIA Ms Surbhi Sharma, ITSMA Ms. Surbhi Sharma, ITSMA 
  • 2. Table of ContentCurrent Scenario of Indian  Biotechnology Current Scenario of Indian Medical TechnologyOpportunitiesLooking Ahead
  • 3. Current Scenario of Indian  Biotechnology Sector 
  • 4. Market Segments Biotechnology Bio‐ BioinformatBio‐pharma Bio‐services Bio‐agri industrials icsThis sector  Bio‐services  This  This sector  This sector accounts for  is the  segment  accounts to  offers majority of  second‐ accounts to  about € 89  several biotech’s  largest  about € 307  million. investment industry.  It  contributor  million. opportunityaccounts to  to the  .  It about € 1.3  industry.  It  accounts to billion. accounts  to  about € about € 419  36.7 million. million.
  • 5. Key Players• The leading ten companies (in terms of revenues) accounted for 39 per  cent of the total industry revenues in 2008–09.• MNCs such as Novo Nordisk and Novozymes feature among the leading 10  biotech companies.• Of the top 20 companies, 19 of them generated revenues worth € 14.6  million in 2008–09.• The leading 30 home‐grown companies contributed revenues worth € 0.9  billion, accounting for 57 per cent of the total revenues of the industry in  2008–09.• Serum Institute of India and Biocon are the two leading players in the  industry.
  • 6. Current Scenario of Indian Medical  Technology
  • 7. Market Segments Pharmaceuticals Contract research  Active pharmaceutical and manufacturing  Formulations ingredients (APIs) services (CRAMS)India is a fast growing  India’s manufacturing  India is the third‐largest custom manufacturing  prowess in  player in the world with  and research  formulations is  500 different APIs.  outsourcing  validated by the fact  destination with a  that it manufactures  growth rate that is  60,000 packs across  thrice the global  60 therapy areas.  market rate.
  • 8. Key PlayersCompany No of Beds PresenceApollo Hospitals  4356 Chennai, Madurai, Hyderabad, Karur, Enterprise Ltd KarimNagar, Mysore, Visakhapatnam, Bilaspur,  Aragonda, Kakinada, Bengaluru, Delhi, Noida,  Kolkata, AhmedabadAravind Eye Hospitals 3537 Theni, Tirunelveli, Coimbatore, Puducherry,  Madurai, Amethi, KolkataCARE Hospitals 1666 Hyderabad, Vijaywada, Nagpur, Raipur,  Bhubaneshwar, Surat, Pune, VisakhapatnamFortis Healthcare  5044 Mumbai, Bengaluru, Kolkata, Mohali, Noida, Limited Delhi, Amritsar, Raipur, Jaipur, Chennai, KotaMax Hospitals  800 Delhi and NCRManipalGroup of  +7000 Udupi, Bengaluru, Manipal, Attavar, Mangalore, Hospitals Goa, Tumkur, Vijaywada, Kasargod,  Visakhapatnam
  • 9. Opportunities
  • 10. Opportunities – Biopharma• The growth in the biosimilars market is  driven by an increasing use of biologics in  disease areas such as cancer, auto‐ Segment  Potential immune and orphan diseases and cost  Bio‐ € 1.45 containment. pharmaceuticals  Bio‐services € 0.72• Companies in this segment include  Reliance Biopharma, Shantha Biotech,  Panacea Biotec, Wockhardt, Dr Reddy’s,  Biocon, Intas Biopharmaceuticals and  Avesthagen.• Glenmark and Cipla are targeting new  product launches in 2010.
  • 11. Opportunities —bio‐similarsIncreasing use of biologics in disease areas such as cancer, auto‐immuneand orphan diseases, in addition to healthcare cost containment, has driven the growth of bio‐similars.Companies in this space include • Reliance Biopharma • Shantha Biotech • Panacea Biotec • Wockhardt • Dr Reddy’s • Biocon • Intas Biopharmaceuticals and • AvesthagenGlenmark and Cipla are targeting new product launches in 2010.
  • 12. Looking Ahead• India is already being globally recognised as a  manufacturer of economical, high‐quality bulk drugs and  formulations. • With a huge base of talented, skilled and cost‐ competitive manpower, and a well‐developed scientific  infrastructure, India has great potential to become a  leading global player in biotechnology.• According to a report by PricewaterhouseCoopers (PwC)  in April 2010, India will join the league of top 10 global  pharmaceuticals markets in terms of sales by 2020 with  the total value reaching €37.82 billion.
  • 13. Thank You! Thank You!surbhi@itsmaindia.org surbhi@itsmaindia.org